Autologous peripheral stem-cell transplantation

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Autologous peripheral stem-cell transplantation (APSCT) is crucial for cancer patients undergoing high-dose chemotherapy (HDCT).
• HDCT can cause prolonged or irreversible myelosuppression, necessitating hematopoietic reconstitution (HR).
• APSCT involves harvesting, cryopreserving, and reinfusing a patient's own progenitor cells for HR.

Purpose of the Study:

• To assess the safety, efficacy, and cost-effectiveness of using peripheral stem cells (PSC) for HR in APSCT.
• To review patient selection criteria and indications for APSCT.
• To compare APSCT with autologous bone marrow transplantation (ABMT).

Main Methods:

• Review of available information from study panels, research centers, institutions, and government agencies.
• Discussion of randomized clinical trials and their limitations.
• Comparison of HR rates and patient outcomes between APSCT and ABMT.

Main Results:

• Peripheral stem cells (PSC) can provide satisfactory hematopoietic reconstitution (HR).
• The rate of HR using PSC is comparable to that of autologous bone marrow transplantation (ABMT).
• Current techniques for CD34+ cell separation in APSCT reduce tumor cell infusion compared to unseparated PSC.

Conclusions:

• Existing evidence supports the use of PSC for satisfactory HR in APSCT.
• The clinical significance of HR via PSC is secondary to the antitumor benefits of HDCT.
• APSCT using PSC is a viable option for supporting cancer patients post-HDCT.